Kafr Al Sheikh First

The trial focuses on adults aged 18 to 65 with sudden sensorineural hearing loss (SSNHL), a rapid hearing loss of 30 dB or more across three consecutive frequencies occurring within 72 hours. Researchers are comparing the effects of a single course of intratympanic (IT) administration of dexamethasone-loaded exosomes against conventional IT dexamethasone and exosome vehicle alone. The study aims to assess improvements in hearing, safety, tolerability, and inner ear drug delivery effectiveness, considering the challenges posed by anatomical barriers in conventional treatments. Participants will receive one of three treatments: IT dexamethasone-loaded exosomes, conventional IT dexamethasone, or exosome vehicle alone. Exosomes are tiny natural vesicles derived from human umbilical cord mesenchymal stem cells, designed to improve drug delivery to the inner ear by crossing biological barriers and enhancing retention. The study includes advanced imaging techniques to study drug distribution and pharmacokinetics in a sub-study if applicable. During the study, participants will have their hearing tested using pure-tone average (PTA) measurements at various time points up to six months post-treatment. Additional assessments include auditory brainstem response thresholds and otoacoustic emissions to evaluate auditory function. Researchers will monitor safety, tolerability, and recovery rates of hearing improvement at 1, 4, and 12 weeks. The entire participation period involves follow-up evaluations to thoroughly assess treatment effects and side effects.

This research aims to evaluate the safety and effectiveness of acetyl-leucine in patients who have post-stroke ataxia following a posterior-circulation ischemic stroke. The study is a phase 3, double-blinded, placebo-controlled trial conducted at Kafr-Elsheikh University between January 1, 2026, and July 1, 2026. It includes 200 patients who recently suffered their first ischemic stroke affecting the back circulation of the brain, assessing balance and ataxia symptoms using clinical scales such as the Berg Balance Scale (BBS), Scale for the Assessment and Rating of Ataxia (SARA), and the Modified Rankin Scale (mRS). The study also monitors potential side effects related to the treatment.

Carpal tunnel syndrome (CTS) is a common nerve compression disorder affecting the wrist, caused by pressure on the median nerve within the carpal tunnel. This research evaluates how ultrasound (US) and nerve conduction studies (NCS) can be used to diagnose CTS, plan treatment, and monitor patients over time. Ultrasound offers a non-invasive, quick way to assess the median nerve's size, blood flow, and movement, as well as identify anatomical differences that might contribute to CTS. Participants will undergo high-resolution ultrasound imaging of both wrists using a 12 MHz linear array transducer. These ultrasound exams will be done before surgery and repeated three months after surgery to monitor changes. This procedure aims to determine the value of ultrasound in managing CTS alongside nerve conduction studies. During the study, patients will have ultrasound evaluations and nerve conduction tests to assess nerve function and structure. Researchers will measure how sensitive ultrasound is in diagnosing CTS by comparing it with surgical findings. The study will track patient progress through clinical assessments and imaging, with follow-up occurring at three months post-surgery. The total involvement duration depends on the surgical timeline and follow-up visits.

Researchers are investigating how the length of time symptoms have been present affects the outcomes of lumbar spine surgery. This surgery is used to treat various lower back conditions such as degenerative disc disease, spinal stenosis, spondylolisthesis, and disc herniation. Conservative treatments are typically tried first, but surgery may be considered if symptoms persist without improvement after 3 to 6 months, especially when neurogenic claudication and imaging findings support surgical intervention. Surgery has been observed to improve disability and pain for at least four years compared to conservative care, though benefits may diminish over time. The study involves patients undergoing lumbar spine surgery who have symptoms like back pain, radiculopathy, neurogenic claudication, weakness in the legs, or bowel/bladder issues. The surgery is the main intervention being studied. Participants will be evaluated to understand how the duration of their symptoms before surgery impacts their recovery and outcomes. Participants will be assessed for disability six months after surgery to measure the effectiveness of the treatment. Throughout the study, medical evaluations will focus on symptom changes and functional abilities. The total duration of involvement includes the pre-surgery period and a follow-up at six months postoperatively, during which disability and recovery progress are closely monitored.

Researchers are evaluating the pain relief and functional recovery after knee surgeries by comparing two types of nerve blocks: blocking the nerve to the vastus lateralis muscle (NVL) versus the lateral femoral cutaneous nerve (LFCN). The study focuses on how effectively these nerve blocks manage postoperative pain, which is important to help patients move early and recover faster after surgery. Ultrasound guidance is used for precise delivery of the nerve blocks. Participants receive either a vastus lateralis nerve block or a lateral femoral cutaneous nerve block, each consisting of 5 ml of bupivacaine 0.5%. These nerve blocks are given after knee surgery under spinal anesthesia. The study is designed as a randomized trial to compare the effects of these two treatments. During the study, researchers assess the degree of pain 24 hours after surgery to measure the effectiveness of the nerve blocks. They also monitor for any side effects or complications. The study includes adult participants aged 18 years and older who have undergone knee surgery. The overall goal is to find which nerve block provides better pain control and improved functional outcomes after knee surgery.

The trial investigates outcomes in patients with osteoporotic spines who need surgical stabilization through posterior instrumentation. It compares two types of pedicle screw fixation methods: bone cement augmented transpedicular screws and cannulated pedicle screws. The study focuses on implant stability, pain relief, functional recovery, and complication rates, addressing challenges caused by low bone mineral density in osteoporosis that increase risks of screw loosening and fixation failure. Participants will receive either bone cement augmented transpedicular screw fixation or cannulated pedicle screw fixation. These procedures involve implanting screws to stabilize the spine, with the bone cement method designed to reinforce screw fixation by injecting cement through the screw. Both methods aim to improve implant stability in osteoporotic bone. The study tracks these interventions with respect to their clinical and radiological effects. During the study, participants will be monitored for outcomes including implant stability and wound infection, with infection assessed six months after the procedure. Researchers will evaluate pain relief, functional recovery, and any complications arising. Assessments will include clinical examinations and imaging studies to compare the effectiveness and safety of the two fixation methods in managing osteoporotic spinal conditions.

Researchers are evaluating the effects of combining intrathecal dexmedetomidine with an adductor canal block to manage pain after total knee arthroplasty (TKA). Effective pain control after knee surgery is important to improve recovery, help patients move sooner, and reduce complications. This study focuses on how these two methods together affect analgesia after TKA surgery. Participants will receive different combinations of treatments at the end of their surgery. One group gets 15mg of hyperbaric bupivacaine with 5 micrograms of dexmedetomidine intrathecally plus an adductor canal block using 20 ml of bupivacaine 0.25%. Another group receives the same bupivacaine dose intrathecally with saline plus an adductor canal block with bupivacaine 0.25%. A third group gets bupivacaine and dexmedetomidine intrathecally with saline for the adductor canal block. These treatments are given to assess their combined effect on pain relief. Participants will be monitored for total morphine consumption in the 48 hours after surgery as the primary outcome measure. The study involves careful assessment of pain control and medication use following the treatments. Researchers will also track safety and recovery progress during this period to understand how the combined approach impacts patient outcomes after TKA.

Researchers are evaluating the effectiveness and safety of combining aspirin with either clopidogrel or cilostazol in patients who have experienced their first large-vessel minor ischemic stroke or transient ischemic attack (TIA). This phase 3 randomized controlled trial aims to compare a 300 mg loading dose of clopidogrel plus aspirin versus a 200 mg loading dose of cilostazol plus aspirin, assessing outcomes such as stroke recurrence and hemorrhagic complications over 90 days. The study includes adults aged 18 to 75 years who receive antiplatelet treatment within 24 hours of stroke onset and excludes those eligible for certain treatments or with specific medical conditions. Participants are randomly assigned to one of two groups: the clopidogrel arm receives a 300 mg loading dose followed by 75 mg daily for 90 days alongside aspirin, while the cilostazol arm receives a 200 mg loading dose followed by 100 mg twice daily for 90 days with aspirin. Both groups receive a 300 mg loading dose of aspirin and 75 mg daily thereafter. The study involves clinical assessments including stroke scales and functional status at admission, day 7, and 90 days, along with brain imaging such as MRI and CT scans when necessary. Throughout the study, patients undergo detailed clinical evaluations, risk factor profiling, and monitoring including echocardiography, ECG, carotid duplex, and laboratory testing. Researchers measure the rate of new strokes and drug-related bleeding events at 90 days as primary outcomes. Secondary outcomes include improvement in neurological scores, functional recovery, and rates of recurrent vascular events. Safety is monitored via adverse effect questionnaires and follow-up visits, with data collected through face-to-face interviews and clinical assessments over the 90-day period.

Researchers are evaluating the safety and effectiveness of combining aspirin with either clopidogrel or cilostazol in adults aged 18 to 75 who have experienced their first minor ischemic stroke or transient ischemic attack (TIA). This phase 3 randomized controlled trial aims to compare a 300 mg loading dose of clopidogrel given within 24 hours of stroke onset to a 200 mg loading dose of cilostazol, assessing outcomes like stroke recurrence and bleeding complications over 90 days. Participants are divided into two groups: one receiving clopidogrel with a 300 mg loading dose followed by 75 mg daily from day 2 to day 90, and the other receiving cilostazol with a 200 mg loading dose followed by 100 mg twice daily from day 2 to day 90. Both groups also receive aspirin loading and maintenance doses. Clinical evaluations, risk factor assessments, and brain imaging (CT and MRI) are performed during the study to monitor progress and safety. Throughout the 90-day study, patients undergo assessments including neurological scales (NIHSS, Modified Rankin Scale) at admission, day 7, and three months. Additional tests include echocardiography, ECG monitoring, carotid ultrasound, blood tests, and questionnaires to identify adverse effects. The main outcomes measured are rates of new stroke and drug-related bleeding complications at 90 days, along with secondary outcomes like neurological improvement, functional recovery, and vascular events.

Researchers are evaluating the safety and effectiveness of combining aspirin with either ticagrelor or cilostazol in adults aged 18 to 75 who have experienced their first minor stroke or transient ischemic attack (TIA) caused by large vessel blockage. This Phase 3 randomized controlled trial aims to compare a 180 mg loading dose of ticagrelor given within 24 hours of stroke onset to a 200 mg loading dose of cilostazol, assessing outcomes such as stroke recurrence and drug-related bleeding complications over 90 days. The study also monitors neurological improvement and adverse effects using clinical scales like NIHSS and the Modified Rankin Scale.